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                                        ABSTRACT 
 
 
MicroRNAs are a class of small endogenous RNA molecules that is involved in the post-
transcriptional inhibition of gene expression. They directly interact with target gene transcripts 
and influence cellular physiology. MicroRNAs have been reported to be involved in breast 
cancer tumorigenesis and metastasis thus playing a vital role in cancer progression.  Our study 
aims at identification of novel miRNA-mRNA target pairs that are hypothesized to play a role in 
breast cancer through a miRNA- mRNA interaction map analysis of microarray data and 
experimental validation of selected set of mRNAs. The target interaction map analysis revealed 
three novel target pairs, hsa-miR-27a–MARCKS, hsa-miR-27a–SIK1 and hsa-miR-21–BTG2 
which can be potential therapeutic targets in breast cancer. Therefore, with the better 
understanding of the regulation of miRNAs, the gene networks and cellular pathways regulated 
by miRNAs, it will be of immense significance to further comprehend breast cancer pathogenesis 
and target interaction as a therapeutic for breast cancer. 
 
Keywords: microRNAs, transcriptional inhibition, gene expression, tumorigenesis, metastasis, 
microarray, target interaction map 
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INTRODUCTION 
Breast cancer is the most commonly diagnosed cancers in women which is the second 
leading cause of cancer deaths that accounts for approximately 22% of all new cancer cases 
worldwide. It is seen that more than one million new cases arise every year. Globally, 0.45 
million patients die from breast cancer annually, which constitutes 13.7% of female cancer 
deaths (Parkin, 2001 and Jemal et al. 2011). Breast cancer is prone to metastasis involving 
secondary sites such as the lung, liver, bone, and brain. Metastasis is seen to occur even after 
many years of the removal of the primary tumor, minimizing the survival rate from 85% for 
early detection to 23% for patients with lung or bone metastasis, therefore being the main cause 
of death for breast cancer patients (Lorusso, 2012). Genetic mutations are said to be the 
contributing causes of tumorigenesis and metastasis in breast cancer. Presently, the mechanisms 
for controlling metastasis are poorly understood and thus the treatments for metastatic late-stage 
breast cancer are still inefficient (Lee, 2012). Hence, it is of a great clinical importance to 
understand the molecular mechanisms involved in primary tumor cell invasion and its spread to 
distant sites, and thus to identify new molecular targets for cancer therapies. 
In the recent past, microRNAs (miRNAs) got revealed as the focal point in the molecular 
dissection of human cancer (Calin et al., 2002). An emerging list of information recommends 
that microRNAs critically participate in cancer initiation and progression. Evidences have shown 
that microRNAs play a vital role in breast cancer. Such MicroRNAs have been described as a 
family of small, noncoding, double-stranded RNA molecules of short 18 to 25 nucleotides 
noncoding genes excised from 60-110 nucleotide hairpin RNA precursors that is involved in the 
regulation of expression of protein-coding genes (PCGs). Consequently it is seen that the events 
that activate or inactivate miRNAs were said to cooperate with PCG abnormalities in human 
tumorigenesis (Porter et al., 2008).  
Hundreds of miRNAs have been identified till date in mammals, some of which are 
expressed in a tissue-specific and developmental stage-specific way. Since the discovery of this 
regulatory RNA phenomenon, much progress has been made in recent times towards 
understanding the mechanisms by which this process occurs and in the identification of cellular 
machinery involved in RNA-mediated silencing (Novina et al., 2004 and Meister et al., 2004).  
The miRNAs generally interact with target mRNAs with only partial or imperfect 
complementarity by causing either mRNA degradation or translation inhibition and can 
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negatively regulate the expression of target genes with their complementary sequence in cells 
(Novina et al., 2004 and Meister et al., 2004). More recently, it is cited that miRNA down 
regulation was recommended to play a role in cancer progression (Johnson et al., 2005 and 
Cimmino, et al., 2005).  
MicroRNAs play essential roles in normal cellular development but may functionally act 
as either oncogenes or tumor suppressors by targeting analogous oncogenes or tumor suppressor 
genes (Chen, 2005). MicroRNAs possess the capacity to directly target gene transcripts and 
influence cellular physiology that is involved in cancer etiology. As miRNAs can elucidate their 
function through regulation of specific mRNAs, there has been an immense interest in 
identifying their targets. Among the differentially expressed miRNAs in breast cancer, miR-10b, 
miR-125b, miR-145, miR-21, and miR-155 were revealed to be the most consistently 
deregulated. The down regulation of miR-10b, miR-125b, and miR-145 and up regulation of 
miR-21 and miR-155 suggested that these miRNAs could play a role as tumor suppressor genes 
or oncogenes (Enders et al, 2009). 
The efficacy of miRNA-based breast cancer therapy has been explored by emerging 
studies emphasizing their importance in breast cancer. A better understanding of the gene 
networks and cellular pathways regulated by miRNAs will facilitate further elucidation of breast 
cancer pathogenesis and therapy. This can be accomplished by identifying the genome-wide 
targets of miRNAs that is vital.  
In our present study, we sought to generate an miRNA- mRNA interaction map for                  
identification of novel mRNA-miRNA target pairs that are hypothesized to play a role in breast 
cancer through an mRNA- miRNA interaction map analysis of microarray data and experimental 
validation of selected set of mRNAs which has not been reported yet and may be helpful in 
treatment of breast cancer through miRNA therapeutics.                     
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REVIEW OF LITERATURE 
Cancer is defined by the uncontrollable growth and proliferation of abnormal cells inside the 
body. Characteristic immortality of cancer cells lead to their growth and invasion into other 
adjacent tissues and form a tumor. Cancer cells have the potential to pass into the bloodstream or 
lymph vessels and travel to other parts of the body, where they can grow and form new tumors 
that replace normal tissue through a process called metastasis. 
Based on such characteristics tumors are categorized into two types. They are: 
• Benign tumors: Generally considered as non-cancerous, benign tumors form mass of 
cells that lacks the ability to invade adjacent tissue or spread to distant sites by 
metastasizing and generally have a slower growth rate. These tumors are typically 
surrounded by an outer surface or fibrous sheath of connective tissue or remain with the 
epithelium. They can usually be removed from the body and in most case they never 
come back.  
• Malignant tumors: These are characterized by a mass of cells which divide and grow 
uncontrollably, are capable of invading into adjacent tissues and spreading to distant 
tissues to become progressively worse and potentially resulting into death. Malignancy 
in cancers is characterized by  invasiveness, anaplasia and metastasis.  
Characterized by a myriad of aspects, Cancer is considered not just as a disease rather as a group 
of diseases that causes uncontrolled growth of abnormal cells in the body. Cancers can be 
classified on basis of the tissue from which they originate or on basis of the location in the body 
where they first develop.  
 
Therefore, the different types of cancer classification are illustrated below: 
a) On the basis of Tissue and Blood classifications of cancer: 
• Carcinoma- It is a cancer found in body epithelial tissue that covers or lines 
surfaces of organs, glands, or body structures. It accounts for almost 80-90% of 
all cancer cases.  For example: Stomach cancer and Breast cancer. 
• Sarcoma- It is a malignant tumor growing from connective tissues, such as 
cartilage, fat, muscles, tendons and bones.  It usually occurs in young adults. For 
example: Osteosarcoma (bone) and Chondrosarcoma (cartilage). 
 
Page | 4  
 
• Lymphoma- It is a cancer that originates in the nodes or glands of the lymphatic 
system, in the function in production of white blood cells and cleaning body 
fluids, or in organs such as the brain and breast. It is of two types: Hodgkin’s 
lymphoma and Non-Hodgkin’s lymphoma.   
• Leukemia- It is a cancer of the bone marrow that restricts the marrow from 
producing normal red and white blood cells and platelets. It is also known as 
Blood cancer. WBCs are needed to resist infection; RBCs are needed to prevent 
anemia and Platelets keep the body from easy bruising and bleeding. For 
example: Acute lymphocytic leukemia, chronic lymphocytic leukemia 
myelogenous leukemia and chronic myelogenous leukemia. 
• Myeloma- It grows in the plasma cells of the bone marrow. It is of two types: 
Plasmacytoma where the myeloma cells accumulate in one bone and form a single 
tumor and Multiple myeloma where the myeloma cells form many bone tumors 
by accumulating in many bones. 
• Blastoma- It is a cancers derived from immature "precursor" cells or embryonic 
tissue. It is more common in children than in older adults. 
 
b) On the basis of tissue origin: (Table 1) 
• Epithelial tissue tumor- Epithelial tissue consists of skin tissue that covers and 
lines the body as well as covering all the body organs such as the digestive system 
organs and lining the body cavity such as the abdominal cavity and chest cavity. 
The epithelial cells cancers are called carcinomas. There are different types of 
epithelial cells and these can develop into different types of cancer. For example: 
Squamous cell carcinoma (squamous cells of the skin lining of oesophagus), 
Adenocarcinoma (glandular cells of kidney cells or breast cells), Transitional cell 
carcinoma (transitional cells of lining of bladder). 
• Mesenchymal or Connective tissue tumor- Cancers of connective tissues are 
called sarcomas. Mesenchymal or Connective tissues are the supporting tissues of 
the body such as the bones, cartilage, tendons and fibrous tissue that support the 
body organs. Sarcomas are much less common than carcinomas and can develop 
Page | 5  
 
from bone, cartilage and muscle. They are usually grouped into two main types - 
bone sarcomas (osteosarcoma) and soft tissue sarcomas. For example: 
Chondrosarcoma (cancer of cartilage) and Rhabdomyosarcoma (cancer of a 
muscle).  
• Blood and Lymph tissue tumor- There are many different types of blood 
and lymph tissue cells. Haematopoetic tissue is the tissue present in the bone 
marrow that is responsible for the formation of blood cells. Blood tissue can 
develop into Leukemias (cancer of the blood cells) and lymph tissue can develop 
into Lymphomas (cancer of the lymphatic system).These are the most common 
type of cancer affecting children. Brain tumors are the biggest group of rare 
cancers which develop from special connective tissue cells called glial cells that 
support the nerve cells in the brain. The cancers of the glial cells are called 
Gliomas. 
c) On basis of location in the body: 
           Cancers are also named by their origin of initiation apart from its spread to other 
areas. For example, breast cancer that has spread to the liver is still called breast cancer, 
not liver cancer. Similarly, prostate cancer that has spread to the bone is called metastatic 
prostate cancer, not bone cancer. Other examples are cervical cancer, oral cancer, etc. 
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Table 1. Tumor Nomenclature 
ORIGIN CELL TYPE BENIGN TUMOR MALIGNANT TUMOR
Epithelial  
Adeno 
Basal cell 
Squamous cell 
Melano 
Terato 
      Mesenchymal  
Chondro 
Fibro 
Hamangio 
Leiomyo 
Lipo 
Meningio 
Myo 
Osteo 
Rhabdomyo 
Blood and Lymph 
Lympho 
Erythro 
 Myelo 
 
 
 
 
Gland 
Basal cell 
Squamous cell 
Pigmented cell 
Multipotential cell 
 
        Cartilage 
Fibroblast 
Blood vessels 
Smooth muscle 
Fat 
Meninges 
Muscle 
Bone 
Striated muscle 
 
       Lymphocyte 
Erythrocyte 
      Bone marrow 
 
Adenoma 
Basal cell adenoma 
Karatoacanthoma 
Mole 
Teratoma 
 
       Chondroma 
Fibroma 
Hemangioma 
Leiomyoma 
Lipoma 
Meningioma 
Myoma 
Osteoma 
Rhabdomyoma 
 
 
 
 
Adenocarcinoma 
Basal cell carcinoma 
Squamous cell carcinoma 
Melanoma 
Teratocarcinoma 
 
Chondrosarcoma 
Fibrosarcoma 
Hemangiosarcoma 
Leiomyosarcoma 
Liposarcoma 
Meningiosarcoma 
Myosarcoma 
Osteosarcoma 
Rhabdomyosarcoma 
 
         Lymphoma 
Erythrocytic leukemia 
Myeloma 
 
 
 
 
 
                    
Page | 7  
 
                    Breast cancer is a malignant tumor originating from breast epithelial tissue, most 
commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. It is 
found mostly in women, but men can get breast cancer rarely. It is estimated that approximately 
greater than 1,300,000 cases of breast cancer are reported each year worldwide out of which 
around 450,000 resulting in deaths.  
 
Types of Breast cancer: 
• Pre-Invasive Breast Cancer 
It is an early stage of cancer, when it is still confined to the layer of cells where it began and is 
named for cancer cells that stay inside the milk ducts or milk sacs (lobules) of the breast. They 
do not spread into deeper tissues in the breast or to other organs in the body.  
1. Ductal carcinoma in situ (DCIS) 
When cancer cells are confined to the ducts it is called Ductal carcinoma in situ. It increases the 
risk of developing invasive breast cancer. It’s important to treat DCIS, to lower the risk of 
developing invasive breast cancer. DCIS can be found in women at any age mostly between 50 
and 59 years old. 
2. Lobular carcinoma in situ (LCIS) 
When cancer cells are confined to the lobules it is called lobular carcinoma in situ. It is not a true 
cancer or pre-cancer. The cells on the inside of the lobules become abnormal in shape and size, 
proliferate and stay inside the lobules in the breast this is called Atypical lobular hyperplasia 
(ALH). If the abnormal cells stay inside the ducts in the breast this is called Atypical ductal 
hyperplasia (ADH). LCIS, ALH and ADH cannot be felt as a breast lump or other breast change 
and these situations are usually found by chance when a woman has undergone a breast biopsy. 
• Invasive Breast Cancer 
It is a type of cancer which already grown beyond the layer of cells spreading to the lymph nodes 
in the breast or armpit area from where it started. These can be either invasive ductal carcinoma 
or invasive lobular carcinoma. 
• Locally Advanced Breast Cancer 
It is larger than 5cm and may have spread from the breast into the lymph nodes or other tissues 
adjacent to the breast. 
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• Metastatic Breast Cancer 
It is the most malignant stage of breast cancer where the disease has spread to distant metastases. 
It primarily metastasizes to the bone, lungs, lymph nodes, liver and brain. Metastatic breast 
cancer cells frequently differ from the preceding primary breast cancer as it has a developed 
resistance to previous treatment. It has a poor prognosis and causes about 90% of deaths.  
             The accurate cause of breast cancer is unidentified and there are no permanent causes for 
breast cancer.  Some of the causes that are associated with breast cancer are: 
• Age: Older woman is at the higher risk of developing breast cancer including over 80% 
of all female breast cancers occurring among women aged 50+ years after menopause.  
• Inheritance: Family history of close relative like sister, daughter and mother who has 
been diagnosed with breast cancer increases the risk factor.   
• Genetics: It plays a more significant role by causing a hereditary syndrome for breast and 
ovarian cancer carrying the BRCA1 and BRCA2 gene mutation. Other mutated genes 
involve p53, PTEN and STK11, CHEK2, BRIP1, ATM and PALB2. 
• Early menopause: Early start onset of menses and early menopause are also associated 
with breast cancer. 
• Radioactivity: Radioactive rays’ exposure is carcinogenic and increases the chances of 
breast cancer. 
• Hormone Replacement Therapy:  Prolonged exposure to the hormones estrogen and 
progesterone for uninterrupted periods can affect breast cancer risks. 
• Exposure to harmful chemicals: Chemical factory workers use harmful chemicals like 
organochlorines. 
• Nullyparity or Late childbearing:  Late childbearing or nullyparity also appear to be a 
minor risk factor in the development of breast cancer. 
• Alcohol consumption - More alcohol for a woman regularly creates higher risk of 
developing breast cancer. (DeSantis et al., 2012 and Breast cancer overview, American 
Cancer Society, 2012)    
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 MicroRNAs 
                  MicroRNAs have been recently reported to be actively participating in initiation 
and progression of breast cancer. Such microRNAs (miRNAs) are described as a class of 
genes that encodes for small non-coding double-stranded RNA molecules of short 18 to 25 
nucleotides noncoding genes excised from 60-110 nucleotide hairpin RNA precursors that is 
involved in the regulation of expression of protein-coding genes (PCGs). It mainly binds the 
3’UTR of the target mRNA depending on the respective miRNA directed sequence, thus 
promoting mRNA degradation at a post transcriptional level or inhibiting the initiation of 
translation by translational repression (Quesne and Caldas, 2010) (Figure 1).  
 
                                Figure 1: Biogenesis of MicroRNA (Samantarrai et al. 2013) 
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Rules of microRNA targeting 
                       MicroRNA targeting follows certain rules. According to such rules pairing of 
mRNA and miRNA requires conserved Watson-Crick paring to the 5’ region of the miRNA, 
centered on nucleotide 2-7 called as the miRNA “seed”. Conserved paring to the seed region can 
also be sufficient on its own for predicting conserved targets above the noise of false positive 
prediction. The highly conserved target has many conserved targets. Nonconserved targeting is 
even more widespread than conserved targeting. The 3’- supplementary pairing are the numerous 
potential pairing possibilities involving the 3’ portion of the miRNA and the UTR. The 3’ pairing 
optimally centers on miRNA nucleotides 13-16 and the UTR region directly opposite this 
miRNA segment. Pairing to the 3’ portion of the miRNA can not only supplement a 7-8mer 
match and can also compensate for a single nucleotide bulge or mismatch in the seed region. 
Presentation of 2-8 nucleotides prearranged in a geometry resembling an A-form helix enhances 
both the affinity and specificity for matched mRNA segment, enabling 7-8 nucleotide sites to 
suffice for most target functions.  
                     Affinity to the seed is stronger than that to the other regions of the RNA. The 
positioning within the 3’UTR at least 15 nucleotide from the stop codon increases site efficacy 
whereas away from the center of long UTR also increases site efficacy. Site efficacy is also 
boosted by AU rich nucleotide composition near the site or other measures of site accessibility 
and by proximity to sites for co-expressed miRNA. Although most miRNA function has been for 
sites in 3’ UTR, targeting can also occur in 5’UTR and open reading frames. The 3’UTRs with 
non-conserved sites are most often found in genes primarily expressed in tissues where the 
cognate miRNA is absent. Target recognition that relies heavily on 7mer nucleotide matches to 
the seed region creates possibility for a lot of non conserved targeting. ORF targeting is expected 
to be much more effective in messages that are already inefficiently translated. The hierarchy of 
site efficacy follows: 8mer>>7mer-m8>7mer-A1>>6mer>no site, with the 6mer differing only 
slightly from no site at all. For genes that should not be expressed in a particular cell type, the 
cell can come to depend on its miRNAs to act as binary off-switches to help to repress target 
protein output to inconsequential levels. Conserved targets have the tendency to be present at 
low levels in the same tissues as the miRNAs. It is seen that more than 90% of the conserved 
miRNA: target interactions involve only a single site to the miRNA, and therefore most of these 
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targets would be expected to be down regulated by less than 50%. miRNA targeting interaction 
can be disrupted by perturbing an endogenous site through homologous recombination. 
MicroRNA target sites tend to reside in an unstable region, and tend to lack stabilizing elements 
called as long stems (Bartel, 2009).  
Role of microRNAs in cancer 
 
Figure 2. Role of microRNAs in hallmarks of cancer 
 Role of microRNAs in Breast cancer metastasis 
 
 MicroRNAs as balancers between suppression and activation:   
                    The involvement of microRNAs in the development of metastases was initially 
discovered by Ma and coworkers from Robert Weinberg’s group who revealed that up regulation 
of miR-10b promote breast cancer invasion and metastasis and are over-expressed in about 50% 
of metastatic breast cancers. They also proved that HOXD10, a homeobox transcription factor is 
the target of miR-10b.  Later, Tavazzoie and colleagues of the Joan Massague group revealed 
that miR-335 suppresses metastasis and migration by targeting the transcription factor SOX4 and 
tenascin C which is an extracellular matrix component. At the same time, Huang and coworkers 
including the Reuven Agami group reported that miR 373 and miR-520c induce cancer cell 
migration and invasion by suppression of CD44. These landmark studies reveal a fine balance of 
microRNAs as activation and suppression of metastasis and identify several targets. 
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Balance between repression of miRNA targets and regulation of miRNA expression: 
                     MicroRNA profiling studies have led to the identification of miRNAs that are 
aberrantly expressed in human breast cancer with miR-145, miR-10b and miR-125b being down 
regulated and miR-21 and miR-155 being up regulated. More recent studies have identified 
microRNA downstream targets and associated particular miRNA expression with prognostic 
information. Also microRNA has been shown either to be consistently down regulated or up 
regulated. Tumor formation may arise due to down regulation of a tumor suppressor miRNA 
and/or over expression of an oncogenic miRNA. Therefore, microRNA has been regarded as the 
key factors in breast cancer that possess both oncogenic and tumor-suppressing roles (Sidney et 
al. 2011; Negrini and Calin. 2008) (Figure 2). 
 
 
Figure 3: MicroRNAs and the significant confirmed targets (PCGs) are shown to be 
involved in initiation (early), progression (intermediate) and metastasis (late) stages in 
tumorigenesis. Initiation and progression stages involves the over expression of oncogenic 
miRNAs i.e. miR-21 and miR-221 results into the down regulation of PTEN & KIT whereas 
down regulation of tumor suppressor miRNAs i.e. miR-16 family and Let-7 family results into 
hyper expression of RAS, CDK6, CDC25 & BCL2. Simultaneously, over expression of 
oncogenic miRNAs i.e. miR-10b, miR-373 and miR-520c results into the down regulation of 
HOXD10 & CD44 whereas down regulation of tumor suppressor gene i.e. miR-335 results into 
hyper expression of SOX4, TNC, PTPRN2 & MERTK respectively in metastasis (Negrini and 
Calin. 2008).  
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 The expression and function of various miRNAs in breast cancer is summarized (Table 2). 
 
Table 2. miRNAs and their targets in breast cancer  
 
MicroRNAs TARGET FUNCTIONAL PATHWAY 
Tumor suppressor miRNAs 
miR-206 
miR-17-5p 
miR-125a, b 
miR-200c 
let-7 
miR-34a 
miR-31 
miR-355 
miR-27b 
 
miR-126 
miR-101 
miR-145 
miR-146a/b 
 
miR-205 
Oncogenic miRNAs 
miR-21 
miR-155 
miR-10b 
miR-373/520c 
miR-27a 
 
miR221/222 
 
 
 
ESR1 
AIB1, CCND1, E2F1 
HER2, HER3 
BMI1, ZEB1, ZEB2 
H-RAS, HMGA2, LIN28, PEBP1 
CCND1, CDK6, E2F3, MYC 
FZD3, ITGA5, M-RIP, MMP16, RDX, 
RHOA 
SOX4, PTPRN2, MERTK, TNC, CYP1B1 
 
IRS-1 
EZH2 
p53-mediated repression of c-Myc 
NF-Κb 
 
ErbB3 and VEGF-A expression 
 
BCL-2, TPM1, PDCD4, PTEN, MASPIN 
RHOA 
HOXD10 
CD44 
Zinc finger ZBTB10, Myt-1 
 
p27Kip1 
 
 
ER signaling 
Proliferation 
Anchorage-dependent growth 
TGF-β signaling 
Proliferation, differentiation 
DNA damage, proliferation 
Metastasis 
Metastasis 
Modulation of the response of tumor to anti-cancer 
drugs 
Cell cycle progression from G1/G0 to S 
oncogenic and metastatic activity 
Suppresses Cell Invasion and Metastasis 
Negatively regulate factor-κB, and impaired 
invasion and migration capacity 
Inhibits tumor cell growth and cell invasion 
 
Apoptosis 
TGF-β signaling 
Metastasis 
Metastasis 
Cell cycle progression G2- M checkpoint 
regulation 
Tamoxifen resistance 
 
                                                                     Source: O’Day and Lal (2010) Sidney W. Fu et al. (2011) 
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Gene interaction network for breast cancer miRNA targets 
 
                   The effectiveness of miRNA-based breast cancer therapy has been explained by a 
better understanding of the gene networks and cellular pathways regulated by miRNAs, by 
identifying the genome-wide targets of miRNAs. It is reported that miRNAs inhibit the 
expression of many genes which signifies that inclusive regulation can be achieved by over 
expressing a single miRNA. Simultaneously the deregulation of miRNAs would consequently 
change the expression of many genes resulting into induced tumorigenesis. The functions of the 
experimentally validated breast cancer miRNAs and their gene targets that might be incorporated 
within the pathogenesis of breast cancer can be better understood by a gene interaction network 
analysis. 
In a study, a list of 34 genes was generated that is recognized to be altered by the 11 
miRNAs. 19 genes formed a well-connected gene interaction network in which MYC act as the 
central node that is a target of miR-34a. Similarly, more highly interacting genes were BCL-2, 
E2F1, CCND1 and ESR1, respectively. The results suggested that breast cancer is associated 
with the alteration in the expression of multiple miRNAs that disturb a network of genes which 
can either activate or inhibit each other’s expression. The down regulation of miR-206 enhanced 
ESR1 and MYC expression. CCND1, E2F1 and E2F3 expressions are activated by MYC 
elevation.  Additionally, miR-17-5p (regulates CCND1 and E2F1) and miR-34a (regulates E2F3, 
CCND1 and CDK6) also elevate the levels of these proteins. Thus suggested that down 
regulation of several tumor suppressor miRNAs may lead to up regulation of oncogenes in breast 
cancer via direct or indirect mechanisms. Increased levels of miR-21 regulate TPM1, miR-31 
target MMP16 and miR-373/520c target CD44 that is seen to be repressed in breast cancer cells. 
The tumor suppressor or oncogenic miRNAs regulate the transcription of some of these genes by 
targeting transcription factors. The gene interaction network essential for breast cancer 
progression undergoes a change due to loss of miRNA regulation leading to a cascade of events 
at different stages of progression and metastasis possibly in most gene regulatory events. Other 
several miRNAs involved in breast cancer are miR-7, miR-128a, miR-210, miR-27b, miR-335, 
miR-126, miR-145 and miR-27a (Blenkiron et al., 2007) (Figure 3).  
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Figure 4. Gene interaction network analysis of miRNA targets in breast cancer. The direct 
interaction network of 34 published targets of 11 miRNAs implicated in breast cancer 
pathogenesis is determined using Ingenuity software and is shown: miR-206, miR-17-5p, miR-
125a/b, miR-200, let-7, miR-34, miR-31, miR-21, miR-155, and miR-373/520c. Central highly 
connected network of targets are formed on MYC. Protein-protein or protein-DNA interactions 
are indicated by arrows suggesting these targets coordinate the expression and/or function of one 
another (Blenkiron et al., 2007). 
 
MicroRNA profiling is a promising and powerful diagnostic tool that can be useful to 
differentiate the characteristics of different tumor types in breast cancer, such as the miRNA 
signatures that can clearly distinguish normal and malignant breast tissue and also categorize 
between breast cancer subtypes. Thus, the detection of the genes regulated by miRNAs and the 
clarification about their integrating mechanisms in breast cancer gene interaction network can 
better support in understanding this malignant disease.  
 
 
 
 
 
 
 
 
OBJECTIVES 
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OBJECTIVES 
 
OBJECTIVE 1 
Microarray expression analysis for identification of differentially expressed mRNA in breast 
cancer 
 
OBJECTIVE 2 
Microarray expression analysis for identification of differentially expressed miRNA in breast 
cancer 
 
OBJECTIVE 3 
Target prediction and generation of miRNA–mRNA interaction map for differentially expressed 
sets of miRNA and mRNA 
 
OBJECTIVE 4 
Identification of novel miRNA–mRNA target pairs involved in breast cancer & experimental 
validation of mRNA expression by RT-PCR in MDA-MB-231 cell lines 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS & METHODS 
 
1)  Gene Expression data 
 
                     The gene expression data is taken in order to conduct a genome wide analysis of 
mRNA and miRNA expression of normal and diseased sample in breast cancer, and also to study 
and distinguish between the various expressions patterns for diagnosis and therapeutic 
mechanisms.  
                      The gene expression data were retrieved from Gene Expression Omnibus (GEO) 
database. GEO a public functional genomics data repository supporting MIAME-compliant data 
submissions that archives and freely distributes next-generation sequencing, microarray and 
other forms of high-throughput functional genomic data submitted by the scientific community. 
A collection of web-based interfaces and applications are available to provide help users query 
and download experiments and curated gene expression profiles stored in GEO. The GEO data 
contains raw microarray data that involves images that are to be converted into gene expression 
matrices, where rows represent genes, columns represent various samples such as tissues or 
experimental conditions, and numbers in each cell illustrate the expression level of the particular 
gene in the particular sample. Analysis of the matrices can be further done in order extract any 
biological process and its understanding. Platform describes the list of features on the array (e.g., 
cDNAs, oligonucleotides, etc.). There is an importance of using different platforms as because of 
the diversity of technical and analytical sources that can affect the results of an experiment. 
Therefore, a comparison among experiments, its standardization within a single platform may be 
inefficient. So, large-scale comparison studies involving microarrays can be done for 
optimum reproducibility measurements using various platforms.  
                     The gene expression data of mRNA and miRNA were taken. The mRNA breast 
cancer data taken were on breast epithelium from reduction mammoplasty of reduction 
mammoplasty patient and breast epithelium adjacent to tumor of breast cancer patient. The 
miRNA breast cancer data taken were on mastectomy samples of Normal breast tissue and 
Invasive breast cancer. Respective mRNA data were chosen in order to find out the mRNA 
differential expression in mammoplasty patient and breast cancer patients. The miRNA data 
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were selected in order to investigate the miRNA differential expression in normal breast tissue 
and invasive breast cancer tissues. 
• The PLATFORM taken were:   
 
mRNA [HG-U133A] Affymetrix Human Genome U133A Array (GPL96) 
 
miRNA Agilent-031181 Unrestricted_Human_miRNA_V16.0_Microarray 
030840 (GPL15018) 
 
 
• The SAMPLE taken were: 
mRNA GSE9574 (Gene expression abnormalities in histologically 
normal breast epithelium of breast cancer patients) 
miRNA GSE38867 (MicroRNAs expression profiling during breast 
cancer progression) 
 
 
2) Microarray analysis of gene expression data- 
 
 
a) Retrieval of gene expression data –  
 
• The SERIES taken for mRNA were:  GSM242005 
                                                                                     GSM242006  
                                                                                     GSM242007 
                                                                                     GSM242020  
                                                                                     GSM242021   
                                                                                     GSM242022 
• The data were taken in triplicates. Samples in an experiment have associated 
experiment parameters and corresponding parameter values, so triplicates were 
taken.  
• The raw files were downloaded in .CEL format. 
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• Then the files were unzipped, extracted and renamed as control and test. 
 
 Control Test 
mRNA GSM242005 
GSM242006 
GSM242007 
GSM242020 
GSM242021 
GSM242022 
 
 
• The SERIES taken for miRNA were:  GSM951044 
                                                             GSM951048 
                                                             GSM951052 
                                                             GSM951046 
                                                             GSM951050 
                                                             GSM951054 
 
• The data were taken in triplicates.  Samples in an experiment have associated 
experiment parameters and corresponding parameter values, so triplicates were 
taken.  
• The raw files were downloaded in .CEL format. 
• Then the files were unzipped, extracted and renamed as control and test. 
 
 Control Test 
miRNA GSM951044 
GSM951048 
GSM951052 
GSM951046 
GSM951050 
GSM951054 
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b) Analysis of gene expression data- 
 
                   The software used for gene expression analysis was Genespring GX software. It is a 
powerful microarray expression data analysis tool sold by Agilent, and something of a standard 
for such task which consists of a wide range of analytical algorithms for gene expression 
microarray experiments. It is used for identifying classes of transcripts that show expression 
patterns that are correlated with the experiment variables, displaying these transcripts against a 
backdrop of biochemical pathways and querying for transcripts using e.g., gene symbol, gene 
name or GO ontology terms.  
 
                  Working in GeneSpring GX is organized into projects. A project comprises one or 
more related experiments. An experiment comprises samples (i.e. data sources), interpretations 
(i.e. groupings of samples based on experimental parameters), and analyses (i.e. statistical steps 
and associated results, typically entity lists). Statistical steps and methods of analysis are driven 
by a workflow which finds prominent mention on the right side of GeneSpring GX.  
 
                 A project is the key organizational element in GeneSpring GX. It is a container for a 
collection of experiments. For example, one experiment measures gene expression profiles of 
individuals with and without breast cancer. A new project can be created from Project −New 
Project by just specifying a name for the project and optionally any user notes. 
 
               An experiment in GeneSpring GX represents a collection of samples for which arrays 
have been run in order to answer a specific scientific question. A new experiment is created from 
Project −New Experiment by loading samples of a particular technology and performing a set of 
customary pre-processing steps like, normalization, etc., that will convert the raw data from the 
samples to a state where it is ready for analysis. An experiment consists of multiple samples, 
with which it was created and multiple interpretations by grouping these samples by user-defined 
experimental parameters, and all other objects created as a result of various analysis steps in the 
experiment. 
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           An experiment comprises a collection of samples. These samples are the actual 
hybridization results. Each sample is associated with a chip type or its technology and will be 
imported and used along with a technology. 
 
           GeneSpring GX technology contains information on the array design as well as biological 
information about all the entities on a specific array type. A technology initially must be installed 
for each new array type to be analyzed. For standard arrays from Affymetrix, Agilent and 
Illumina, technologies have been created.  An experiment comprises samples which all belong to 
the same technology. 
 
Steps followed for gene expression analysis in GeneSpring:- 
 
• For mRNA expression analysis: 
  
                 Normalization of the data was done to minimize systematic non-biological 
differences to reveal true biological differences, which may include systematic variations from 
sources like unequal quantities of starting RNA, differences in hybridization between chips and 
differences between manufactured chips in microarray experiments. Profile plot of Normalized 
intensity map values is obtained after Normalization of data. Data is normalized to 75th 
percentile of signal intensity to standardize each chip for cross-array comparison. The main 
objective is for eliminating redundancy and ensuring that the data make sense with minimum 
number of entities. 
 
                An option of Create new experiment was chosen that allows creating a new 
experiment. The Experiment type should then be specified as Affymetrix Gene Chip-HG-
U113A. Once the experiment type is selected, the workflow type needs to be selected as Guided 
workflow.  
 
              An experiment can be created using choose sample option. Experimental setup was 
done by adding average parameter to help define the experimental grouping as test and control 
and replicate structure of the experiment. 
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             Quality control of samples was done by Filter Probesets by Errors. This operation is 
performed on the raw signal values. The cutoff for filtering is set at 20 percentile of all the 
intensity values and generates a profile plot of filtered entities. The plot is generated using the 
normalized (not raw) signal values and samples grouped by the active interpretation. 
 
            Depending upon the experimental grouping, the Significance Analysis was done by 
performing T-test unpaired analysis as there are 2 groups, i.e. the Control and the Test, with 
replicates. 
 
                Statistical analysis was done by T-test unpaired as a test choice. The test has been used 
for computing p-values, type of correction used and P-value computation type by Asymptotic 
method. It assumes expression values for a gene within each population which is normally 
distributed and variances are equal between populations. The p-value cut-off taken was ≤ 0.05. 
  
              Multiple testing correction was done by using Benjamini-Hochberg FDR algorithm. 
This algorithm is used to reduce the number of false positives or the false discovery rate. This 
correction is the least stringent and tolerates more false positives. There are chances of less false 
negative genes. If the p-value is ≤ 0.05, it is significant. 
 
              Fold change analysis is used to identify genes with expression ratios or differences 
between a test and a control that are outside of a given cutoff or threshold. Fold change gives the 
absolute ratio of normalized intensities between the average intensities of the samples grouped. 
The entities satisfying the significance analysis are passed on for the fold change analysis. The 
fold change cut-off taken is ≥2.0. 
 
              The analyzed data was exported by export entity list with normalized signal values 
consisting of Normalization values, Gene symbol, Entrez gene IDs etc. with interpretation of all 
samples. The entity list was then saved as .txt file. 
              The software used for clustering and generation of Heat map was done by using 
CLUSTER 3.0. It is a program that provides a computational and graphical environment for 
analyzing data from DNA microarray experiments by organizing and analyzing the data in a 
Page | 23  
 
number of different ways. The Cluster program provides several clustering algorithms. 
Hierarchical clustering methods organize genes in a tree structure, based on their similarity and 
assemble a set of items (genes or arrays) into a tree. Items are joined by very short branches if 
they are very similar to each other and longer branches if their similarity decreases. 
              
           The software used for visualization of Heat map was done by Java TreeView which 
allows the organized data to be visualized and browsed by a .cdt file generated through 
CLUSTER 3.0 and was exported as image. 
 
• For miRNA expression analysis: 
  
                 Normalization of the data was done to minimize systematic non-biological 
differences to reveal true biological differences, which may include systematic variations from 
sources like unequal quantities of starting RNA, differences in hybridization between chips and 
differences between manufactured chips in microarray experiments. Profile plot of Normalized 
intensity map values is obtained after Normalization of data. Data is normalized to 75th 
percentile of signal intensity to standardize each chip for cross-array comparison. The main 
objective is for eliminating redundancy and ensuring that the data make sense with minimum 
number of entities. 
 
                An option of Create new experiment was chosen that allows creating a new 
experiment. The Experiment type should then be specified as Agilent_031181. Once the 
experiment type is selected, the workflow type needs to be selected as Guided workflow.  
 
              An experiment can be created using choose sample option. Experimental setup was 
done by adding average parameter to help define the experimental grouping as test and control 
and replicate structure of the experiment. 
  
             Quality control of samples was done by Filter Probesets by Flags. This operation is 
performed on the raw signal values. The cutoff for filtering is set at 20 percentile of all the 
intensity values and generates a profile plot of filtered entities. The plot is generated using the 
normalized (not raw) signal values and samples grouped by the active interpretation. 
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            Depending upon the experimental grouping, the Significance Analysis was done by 
performing T-test unpaired analysis as there are 2 groups, i.e. the Control and the Test, with 
replicates. 
 
                Statistical analysis was done by T-test unpaired as a test choice. The test has been used 
for computing p-values, type of correction used and P-value computation type by Asymptotic 
method. It assumes expression values for a gene within each population which is normally 
distributed and variances are equal between populations. The p-value cut-off taken was ≤ 0.05. 
 
           Multiple testing correction was done by using Benjamini-Hochberg FDR algorithm. 
This algorithm is used to reduce the number of false positives or the false discovery rate. This 
correction is the least stringent and tolerates more false positives. There are chances of less false 
negative genes. If the p-value is ≤ 0.05, it is significant. 
 
              Fold change analysis is used to identify genes with expression ratios or differences 
between a treatment and a control that are outside of a given cutoff or threshold. Fold change 
gives the absolute ratio of normalized intensities between the average intensities of the samples 
grouped. The entities satisfying the significance analysis are passed on for the fold change 
analysis. The fold change cut-off taken is ≥2.0. 
 
              The analyzed data was exported by export entity list with normalized signal values 
consisting of Normalization values, Gene symbol, etc. with interpretation of all samples. The 
entity list was then saved as .txt file. 
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c)  Analysis of the gene list- 
 
                   The common set of genes was analyzed using GO database (Gene Ontology 
database), various technologies like Genomatrix and web based tools like Web based gene set 
analysis tool kit and their involvement in various pathways was studied. From the common set of 
genes two genes were selected based upon their regulation and association with cancer for 
further validation by qRT-PCR. 
                  A set of genes involved in breast cancer with its regulation and fold change value was 
created through export list in an excel file. Similarly, a list of miRNAs involved in breast cancer 
with its regulation and fold change value with cut off ≥2.0 was created. 
 
• For mRNA gene list analysis:  
The analysis was done by comparing the fold change value and regulation of the control 
and test samples. The list of down regulated genes in breast cancer was sorted out.  
• For miRNA gene list analysis:  
The analysis was done by comparing the fold change value and regulation of the control 
and test samples. The list of up regulated miRNAs in breast cancer was sorted out too.  
 
             The genes and miRNAs are chosen on basis of their regulation i.e. highly down 
regulated and highly up regulated. 
 
 
3) Target Interaction Map analysis through Magia2 software: 
 
                The integrated analysis of in silico target prediction, miRNA and gene expression data 
for the reconstruction of post-transcriptional regulatory networks is performed by using software 
called Magia2. The gene expression profile can be resulted because of different levels of 
regulation and a highly connected network of regulatory elements and their interactors. Magia2 
software is a web based tool designed to cope with low sensitivity of target prediction algorithms 
by exploiting the integration of target predictions with miRNA and gene expression profiles to 
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improve the detection of functional miRNA–mRNA, for in silico target prediction through 
miRNA-target expression where regulatory elements and their integrators generate a highly 
interconnected network of mRNA, miRNA and Transcription Factor (TF). Functional 
enrichment of the gene network component can be performed directly using DAVID 
platform.   The miRNA-target interactions experimentally validated (as reported in miRecords 
and TarBase databases) are specifically marked. 
 
The respective data i.e. the gene expression data of mRNA and miRNA expression data 
of miRNA were uploaded and submitted. The analysis was done using Pearson correlation 
method that aims to display the target interaction map for matched miRNAs and gene expression 
data. 
An interaction map was generated where the interconnected network of mRNA, miRNA 
and Transcription Factor were seen. From the interaction map, two genes and two miRNAs were 
selected based upon their regulation and association with breast cancer for further validation by 
qRT-PCR. 
 These selected genes (mRNAs) and miRNAs or the target pairs are not yet been reported 
to be involved in breast cancer. Therefore, web based tool and technology like Genomatrix is 
also used to study their involvement in breast cancer and various pathways. 
 
 
 
4)  Experimental Validation- 
 
 
Cell culture-  
 
                Human breast carcinoma cell line, MDA MB 231 was obtained from National Centre For 
Cell Science (NCCS), Pune, India. The medium used for culturing the cell is MEM (Invitrogen; 
MEM with NEAA (non essential amino acids) and L-Glutamine) with 10% FBS (Fetal bovine 
serum from HIMEDIA) and 1% antibiotic solution (Penstrep solution from HIMEDIA). The 
culture flask containing the cell line is kept in the CO2 incubator with the level of CO2 
maintained at 5%. With the utilization of medium the color of the medium changes from red to 
orange and then pale yellow because of change in pH of the medium.  
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The steps for cell culture was as followed: 
1. The cells were harvested first. 
• Cells were grown in suspension i.e. 1 x 107 cells. The number of cells was determined. 
The appropriate number of cells was pelleted by centrifuging for 5 min at 300 x g in a 
centrifuge tube. Carefully removed all supernatant by aspiration completely from the cell 
culture medium. 
• To trypsinize and collect cells: The number of cells was determined. The medium was 
aspirated, and the cells were washed with PBS. Then the PBS was aspirated, and 0.1–
0.25% trypsin in PBS was added. After the cells detach from the flask, medium 
(containing serum to inactivate the trypsin)was added , the cells were transferred  to an 
RNase-free glass or polypropylene centrifuge tube and centrifuged at 300 x g for 5 min. 
The supernatant was aspirated completely, and proceeded to step 2.  
2. The cells was disrupted by adding Buffer RLT: 
• For pelleted cells, loosen the cell pellet thoroughly by flicking the tube. 350 μl Buffer 
RLT was added. Vortexed or pipetted to mix, and ensured that no cell clumps were 
visible and proceeded to step 3. 
3. The lysate was homogenize for 30 s using a rotor–stator homogenizer and proceeded to 
step 4. 
4.  1 volume of 70% ethanol was added to the homogenized lysate, and mixed well by 
pipetting.  Did not centrifuge.        
5. 700 μl of each sample was transferred from step 4, including any precipitate to each 
RNeasy spin column on the vacuum manifold. 
6. The vacuum was switched on and was applied until transfer was complete. Then switched 
off the vacuum and ventilated the vacuum manifold. 
7. 700 μl Buffer RW1was added to each RNeasy spin column. 
8. The vacuum was switched on and was applied until transfer was complete. Then switched 
off the vacuum and ventilated the vacuum manifold. 
9. 500 μl Buffer RPE was added to each RNeasy spin column. 
10. The vacuum was switched on and was applied until transfer was complete. Then switched 
off the vacuum and ventilated the vacuum manifold. 
11. 500 μl Buffer RPE was added to each RNeasy spin column. 
Page | 28  
 
12. The vacuum was switched on and was applied until transfer was complete. Then switched 
off the vacuum and ventilated the vacuum manifold. 
13.  The RNeasy spin columns was removed from the vacuum manifold, and was placed each 
in a 2 ml collection tube. The lids were closed gently, and centrifuged at full speed for 1 
min. 
14.  Each RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 μl RNase 
free water was added directly to each spin column membrane. The lids were closed 
gently, and centrifuged for 1 min at 8000 x g (10,000 rpm) to elute the RNA. 
15.  If the expected RNA yield is >30 μg, then step 15 was repeated using another 30–50 μl 
RNase free water or using the eluate from step 14 (if high RNA concentration is 
required). The collection tubes were reused from step 14. 
 Note: If using the eluate from step 14, the RNA yield will be 15–30% less than that obtained 
using a second volume of RNase-free water, but the final RNA concentration will be higher. 
 
RNA Isolation- 
 
The kit used for RNA isolation was from QIAGEN.  
1. A maximum of 1×107 cells was harvested, as a cell pellet or by direct lysis of/in vessel. 
The appropriate volume of Buffer RLT was added. 
2. 1 volume of 70% ethanol was added to the lysates and mixed well by pipetting. Did not 
centrifuge. Proceeded immediately to step 3. 
3. Up to 700 µl of the sample was transferred, including any precipitation, to an RNeasy 
Mini spin column placed in a 2ml collection tube (supplied). The lid was closed and 
centrifuged for 15s at ≥8000×g.  The flow –through was discarded. 
4. 700 µl Buffer RW1 was added to the RNeasy spin column. The lid was closed and 
centrifuged for 15s at 8000×g.  The flow –through was discarded. 
5. 500 µl Buffer RPE was added to the RNeasy spin column. The lid was closed and 
centrifuged for 15s at ≥8000×g.  The flow –through was discarded. 
6. 500 µl Buffer RPE was added to the RNeasy spin column. The lid was closed and 
centrifuge for 2 min at ≥8000×g.   
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7. The RNeasy spin column was placed in the new 1.5 ml collection tube. 30-50 µl RNase- 
free water was added directly to the spin column membrane. The lid was closed and 
centrifuged for 1min at ≥8000×g to elute the RNA. 
8. If the expected RNA yield is >30 µg, then step 7 was repeated using another 30-50µl of 
RNase- free water, or using the eluate from step-7.  The collection tubes were reused 
from step-7.  
9. The purity and yield of RNA yield was measured by Eppendorf NanoDrop. It is a 
cuvette free spectrophotometer which eliminates the need for other sample containment 
devices and allows for clean up in seconds. It measures 1 µl samples with high accuracy 
and reproducibility. The full spectrum (220nm-750nm) spectrophotometer utilizes a 
patented sample retention technology that employs surface tension alone to hold the 
sample in place. A 1 µl sample is pipetted onto the end of a fiber optic cable (the 
receiving fiber). A second fiber optic cable (the source fiber) is then brought into contact 
with the liquid sample causing the liquid to bridge the gap between the fiber optic ends. 
The gap is controlled to both 1mm and 0.2 mm paths. A pulsed xenon flash lamp 
provides the light source and a spectrometer utilizing a linear CCD array is used to 
analyze the light after passing through the sample. The instrument is controlled by PC 
based software, and the data is logged in an archive file on the PC. 
 
 
 cDNA synthesis- 
 
cDNA synthesis was carried out using SuperScript First-Strand Synthesis System for RT-PCR by 
Invitrogen using oligo dT primers. 
The steps in cDNA synthesis: 
1. Each of the components were mixed and briefly centrifuged before use. 
2. For each reaction, the following in a sterile 0.2 or 0.5ml tube was combined. 
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3. The RNA/primer mixture at 65·c for 5 minutes was incubated, and then placed on 
ice for at least 1 minute.  
4. In a separation tube, the following 2X reaction was prepared by adding each 
component in the indicated order. 
 
Components 
 
1RXn 10 RXns 
10X RT buffer 
 
2 µl 20 µl 
25mM Mgcl2 
 
4 µl 40 µl 
0.1M DTT 
 
2 µl 20 µl 
RNase out TM (400/ µl) 
 
1 µl 10µl 
 
5.  9µl of the 2X reaction mixture was added to each RNA/primer mixture from 
step3, mixed gently and collected by briefly centrifuge. 
6. It was incubate at 42°c for 2 minutes. 
7.  1µl of super script TM II RT was added to each tube. 
8. It was incubate at 42°c for 50 minutes. 
9. The reaction was terminated at 70·c for 15 minutes. Chilled on ice. 
10. The reaction was collected by brief centrifugation. 1µl of RNase H was added to 
each tube and incubated for 20minutes at 37·c. The reaction was used for PCR 
immediately. 
 
Components 
 
Amount 
RNA 
 
4 µl 
10 mM dNTP mix 
 
1 µl 
Primer (0.5µg/µl oligo (dT)12-18 or 2µM gene 
specific primer) 
1µl 
DEPC treated water 4 µl 
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Quantitative Real Time RT-PCR Analysis-  
                 
              Real-time PCR is the continuous collection of fluorescent signal from one or more 
polymerase chain reactions over a range of cycles. Quantitative RT-PCR involves the conversion 
of the fluorescent signals from each reaction into a numerical value for each sample. Fluorescent 
marker is used which binds to the DNA. Therefore, as the number of gene copies increases 
during the reaction so the fluorescence intensity increases. This is advantageous because the rate 
of the reaction and efficiency can be seen. Intercalating fluorescent dyes (e.g. SYBR green) are 
the simplest and cheapest way to monitor a PCR in real-time. The SYBR green dye fluoresces 
only when bound to double-stranded DNA. The major disadvantage of using a dye such as this is 
the lack of specificity. 
 
            The Gene specific primer sequence were obtained from Primer Bank database (Harvard) 
and ordered from the SIGMA GENOSYS. All the primers were desalted and UV absorbance was 
used to assess the quality of primer synthesis. 
Procedure: 
                  To perform PCR using RNA as a starting template which must first be reverse 
transcribed into cDNA in a reverse transcription (RT) reaction, where the cDNA is used as 
template for real-time PCR with gene specific primers.  
Table 3: Primer name and sequence with length and its amplicon size 
Primer name 5’< ----sequence---- >3’ Length Amplicon Size (nts) 
beta actin F 
beta actin R 
CATGTACGTTGCTATCCAGGC
CTCCTTAATGTCACGCACGAT
21 
21 
250 
MARCKS F 
MARCKS R 
AGCCCGGTAGAGAAGGAGG 
TTGGGCGAAGAAGTCGAGGA 
19 
20 
110 
SIK1 F 
SIK1 R 
CTCCGGGTGGGTTTTTACGAC
CTGCGTTTTGGTGACTCGATG
21 
21 
93 
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Real-time PCR was carried out in Eppendorf  Masterplex Real Time PCR.  
1. The primer concentrations were normalized and gene-specific forward and reverse primer  
pair was mixed. Each primer (forward or reverse) concentration in the mixture was 3.5 μl. 
2. The experiment was set up and the following PCR program was made on. A copy of the  
setup file was saved and all PCR cycles were deleted. The threshold frequency taken was  
33%. The cycle temperatures taken were as follows: 
Table 4: Cycle temperature and time for qRT-PCR 
STAGE TEMPERATURE (°C) TIME CYCLE 
Stage 1 95 20 sec 1 
 
Stage 2 
95 
55 
68 
15 sec 
15 sec 
20 sec 
 
40 
 
Stage 3 
95 
60 
95 
15 sec 
15 sec 
15 sec 
 
1 
 
             
                                      Figure 5. Cycle temperature and time for qRT-PCR 
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3. cDNA was diluted 1:20 ratio concentration and the primer was added.   
4. 10 μl of a real-time PCR reaction volume was made. 
5.  The following mixture was made in each optical tube as follows: 
            SYBR Green Mix (2x)                 35 μl 
   cDNA stock (cDNA: dH2O [1:20])                 40 μl 
primer pair mix (3.5 μl each primer) 
 
                 7 μl 
 
6. The dissociation curve analysis was performed with the saved copy of the setup file. 
7.  The real-time PCR result was analyzed with the in-built software. It was also checked 
 to see if there was any bimodal dissociation curve or abnormal amplification plot. 
8. After PCR is finished, the tubes were removed from the machine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSIONS 
 
 
 
 
 
 
Page | 34  
 
RESULTS & DISCUSSIONS 
 
Microarray Analysis 
 
        mRNA Expression analysis result: 
 
 
Figure 6. Analysis of all entities in the sample 
 
                   Figure 7. Statistical analysis by taking the p-value cut-off  ≤ 0.05 
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Figure 8. 225 entities (genes) are identified when Fold change cut-off was taken 
≥2.0  
 
The total entities of differentially expressed genes in breast cancer are 225, out of which 73 are 
down regulated and 152 are up-regulated. 
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  miRNA expression analysis result: 
                 From the miRNA expression analysis we found out that the total number of 
differentially expressed miRNAs in breast cancer is 94 by taking the p-value cut-off ≤ 0.05 and 
fold change cut off ≥2.0, out of which 82 are down-regulated and 12 are up-regulated. 
 
Table 5: List of microRNAs with fold change and its regulation 
microRNA Fold change (cut off ≥2.0) Regulation 
hsa-let-7f 
hsa-let-7i 
hsa-miR-1274a 
hsa-miR-1274b 
hsa-miR-16 
hsa-miR-193b 
hsa-miR-200b 
hsa-miR-21 
hsa-miR-331-3p 
hsa-miR-24 
hsa-miR-27a 
hsa-miR-22 
2.114769 
2.9767618 
5.035936 
2.7655098 
2.2772193 
4.4158297 
2.5386198 
8.594158 
3.0384824 
2.3400607 
2.127638 
2.2989354 
 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
Upregulated 
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Target interaction map analysis result: 
                         The interconnected network of mRNA, miRNA and Transcription Factor was 
generated as an interaction map (Figure 4). 
 
                Figure 9. Interaction Map of mRNAs and miRNAs involved in breast cancer  
 
                                        
 
 
Page | 38  
 
 
Figure 10. The interaction pairs where it is seen that hsa-miR-21 target BTG2 and  
hsa-miR-27a target both SIK1 and MARCKS 
 
                   From the interaction analysis it was seen that the two miRNAs i.e. hsa-miR-21 target 
BTG2 whereas hsa-miR-27a target SIK1 and MARCKS.  The genes MARCKS, SIK1and BTG2 
are reported to be highly down regulated in breast cancer whereas the miRNAs hsa-miR-21 and 
hsa-miR-27a, are reported to be highly up regulated in breast cancer.   
• Using GENOMATRIX the respective pathway, regulation and function of the genes are 
known. 
 
 MARCKS  
                     It is abbreviated as Myristoylated Alanine-rich C kinase Substrate gene which is the 
most prominent cellular substrate for protein kinase C (80 kDa protein, light chain). It is also 
known as MACS, PRKCSL (Homo sapiens). MARCKS gene is the most prominent cellular 
substrate for protein kinase C (Spizz and Blackshear, 1996, 1993). It is localised in the plasma 
membrane and is an actin filament cross-linking protein. Subcellular location of MARCKS is 
more prominent in cytoplasm than the plasma membrane (Seykora et al., 1996). MARCKS binds 
to plasma membranes via the dual actions of a hydrophobic myristoylated N-terminus and a 
polybasic stretch within the so called effector domain (ED) that mediates electrostatic 
interactions with acidic membrane Phospholipids (Brooks et al., 1996). Phosphorylation of 
Page | 39  
 
protein kinase C or binding to Calcium calmodulin displaces MARCKS from the plasma 
membrane inhibiting its association with filamentous actin linking activity with the plasma 
membrane and also its presence in the cytoplasm (Allen and Aderem, 1995). Myristic acid 
targets MARCKS at the N-terminal of glycine to bind the plasma membrane and phosphorylate 
by PKC. This leads to the down-regulation of MARCKS (Jonsdottir et al., 2005 &  Arbuzova et 
al, 2002).  
The protein is involved in cell motility, membrane trafficking, phagocytosis and 
mitogenesis.  These are acidic proteins with high proportions of Alanine, Glycine, Proline and 
Glutamic acid. (Ramsden, 2000). It plays an important role in cell shape, secretion, 
transmembrane transport and cell-cycle regulation. (Finlayson et al.,2009). Recently, MARCKS 
has been implicated in the exocytosis of a number of vessicles and granules such as mucin and 
chromaffin. MARCKS are also seen to interact with TOB1. Also, MARCKS is seen to be 
reported in breast cancer (Finlayson and Freeman, 2009). 
Function:  
• Actin filament binding (in unphosphorylated form) 
• Calmodulin binding 
• Protein kinase C binding 
Pathway: 
• Fc gamma R-mediated phagocytosis 
• BDNF signaling pathway 
• Integration of energy metabolism 
• Regulation of insulin secretion by Acetylcholine 
• Regulation of insulin secretion 
• Effects of Calcineurin in keratinocyte differentiation (Figure 6) 
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        Figure 11. Involvement of MARCKS in keratinocyte differentiation pathway 
 
 
                                    Figure 12. Gene network of MARCKS                 
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SIK1  
              It is abbreviated as Salt Inducible Kinase 1 which is a tumor suppressor gene that plays 
a key role in p53 dependent anoikis. It belongs to protein kinase superfamily i.e. CAMK Ser/Thr 
protein kinase family and AMPK subfamily. It contains one protein kinase domain and one LBA 
domain (Katoh et al., 2004). The arginine-lysine RK region determines the subcellular location 
and its catalytic activity by phosphorylation on Thr-182 taking magnesium as a co-factor (Doi et 
al., 2002). 
             SIK1 is a part of sodium sensing signaling network, mediating phosphorylation of 
PPME1, increase in intracellular sodium. SIK1 is activated by CaMK1 phosphorylating PPME1 
subunit of PP2A leading to dephosphorylation of NA+/K+ ATPase by increasing its activity 
(Kowanetz et al., 2008 and Stewart et al, 2013). 
           Defects in SIK1is reported to be involved in ovarian cancer and breast cancer (Cheng et 
al., 2009). SIK1 expression is found to be significantly lower or down regulated in primary 
breast cancer than the normal breast tissues (Sjöström et al., 2007).  
Function:  
• SIK1 acts as the regulators of muscle cells by phosphorylating and inhibiting HDAC4 
and HDAC5 , leading to expression of MEF2 target genes in myocytes.  
• It also regulate cardiomyogenesis by removing cardiomyoblast from cell cycle via down 
regulation of CDNK1C. 
• It is also known as the regulator of hepatic gluconeogenesis by phosphorylating and 
repressing TORC1/CRTC1  & TORC2/CRTC2  inhibiting CREB activity. 
• It regulates hepatic lipogenesis by phosphorylating and inhibiting SREBF1.  
Pathway: 
• Liver kinase B1 (LKB) signaling events  (Figure 8) 
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                                      Figure 13. LKB1 signalling events in SIK1 
             
                                              Figure 14.  Gene network of SIK1                 
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         Table  6. Diseases reported to be involved with MARCKS & SIK1  
MARCKS SIK1 
malignantsyringoma 
syringoma 
Bipolar disorder 
lymphocytic leukemia 
neuroblastoma 
alzheimer's disease 
Asthma prostatitis 
melanoma    leukemia 
manic-depressive illness    anoxia 
chronic lymphocytic leukemia     
neuronitis 
liver cirrhosis   hepatitis 
Colorectal cancer 
choroiditis   cerebritis 
hepatocellular carcinoma 
retinoblastoma 
prostate cancer 
Breast cancer 
adenocarcinoma 
medullary sponge kidney 
nephrocalcinosis 
nephrolithiasis 
breast cancer 
gastric cancer 
hepatitis 
malaria 
neuronitis 
Fibromyalgia 
Arthritis 
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     BTG2 
                   It is abbreviated as B-Cell Translocation Gene. Also known as 
pheochromacytoma cell-3, NGF-inducible anti-proliferative protein PC3, B-cell 
translocation gene 2 and nerve growth factor-inducible anti-proliferative. The protein 
encoded by this gene is a member of the BTG/Tob family (Putnik et al., 2012). This 
family has structurally related proteins that appear to have anti-proliferative properties. 
This encoded protein is involved in the regulation of the G1/S transition of the cell cycle 
(Möllerström et al., 2010). 
                 The post translational modification involves phosphorylation at Ser-149 by 
MAPK14 and at Ser-147 by MAPK1/ERK2 and MAPK3/ERK1, leading to PIN1-binding 
and mitochondrial depolarization (Takahashi et al., 2011). BTG2 is preferentially 
expressed in quiescent cells, anti-proliferative p53 dependent component of the DNA 
damage cellular response pathway, homolog to murine Pc3/Tis21 and human BTG1 (see 
symbol),at the onset of neurogenesis in single neuroepithelial cells that switch from 
proliferative to neuron-generating division, Tob/BTG1 family. BTG2 is a vital gene 
reported to be involved in breast cancer (Zhang et al., 2013).  
Function: 
• Involved in cell cycle regulation 
• Involved in the growth arrest and differentiation of the neuronal precursors 
• Modulates transcription regulation mediated by ESR1  
• Anti-proliferative protein 
• Involved in mitochondrial depolarization and neurite outgrowth 
 
Pathway: 
• Direct p53 effectors 
• Deadenylation-dependent mRNA decay 
• Cyclins and Cell Cycle Regulation 
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Figure 15. BTG family proteins and cell cycle regulation 
 
 
Figure 16.  Gene network of BTG2             
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Experimental Validation   
    RNA isolation  
 
• 260/280 Ratio: This ratio indicates the absorbance of DNA and RNA at 260 nm and 280 
nm, which is used to assess the purity of DNA and RNA. A ratio is expected 
approximately 1.8 and generally accepted as “pure” for DNA; a ratio of approximately 
2.0 is generally accepted as “pure” for RNA. In either case, if the ratio is significantly 
lower it may indicate the presence of phenol, protein or other contaminants that absorb 
strongly at or near 280 nm.  
 
• 260/230 Ratio: This ratio is used as a secondary measure of nucleic acid purity. The 
260/230 values for “pure” nucleic acid are often higher than the respective 260/280 
values. Expected 260/230 values are normally in the range of 2.0-2.2. If the ratio is 
significantly lower than expected, the presence of contaminants which absorb at 230 nm 
is indicated.  
 
• Here, we got following results of two samples; Sample1 has perfect ratio absorbance in 
260nm and 280 nm wavelengths where Sample2 has less value. 
 
       
• Sample1 = 500.6 µg/ml 
At (260/280) ratio = 1.99 
At (260/230) ratio = 2.01  
 
• Sample 2 = 125.2 µg/ml 
At (260/280) ratio = 1.54 
At (260/230) ratio = 1.10 
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       qRT-PCR 
 
• qRT- PCR melting curve analysis used to quantify nucleic acid, mutation detection and 
for genotype analysis. 
• The melting temperature curve for the two gene MARCKS and SIK1 with respect to 
control , β-actin was observed. 
 
 
          Figure 17. Melting temperature curve of MARCKS and SIK1 with respect to control 
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• From the qRT PCR analysis of SIK1, a fine melting temperature curve of SIK1 is 
observed in comparison to the control gene, β-actin. The melting temperature of SIK1 is 
82°c. As the samples of gene were taken in triplicates. Three peaks of SIK1 positioned at 
one place were observed. The relative quantification of SIK1 with respect to β-actin 
shows high expression of SIK1 (Figure 13). 
     
       Figure 18. Melting temperature curve of SIK1 with respect to control 
• But MARCKS has no result in qRT- PCR (Figure 14). 
 
    Figure 19. Melting temperature curve of MARCKS with respect to control 
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            Figure 20. Relative expression of MARCKS and SIK1 with respect to control 
 
The graph shows down-regulation of MARCKS and SIK1 with respect to control.  According to 
our microarray data analysis these two genes were down regulated in BC. It was further validated 
by qRT PCR. This is in accordance to studies reported by Li et al., 2009 and Lönn P et al., 2012. 
From the microarray data analysis we found out that MARCKS is down regulated with a fold 
change of 0.34107733 and SIK1 is down regulated with a fold change of 1.9210892.   
As the genes are down regulated, therefore from the miRNA-mRNA interaction map we have 
seen that MARCKS and SIK1 are targeted by miR-27a. Also, BTG2 was found to be targeted by 
miR-21. Therefore, 3 target pairs, hsa-miR-27a–MARCKS, hsa-miR-27a–SIK1 and hsa-miR-21–
BTG2 have been hypothesized to be good target pairs to be validated further by luminometer or 
Luciferase Reporter Assay. 
 
 
 
 
 
0.01
0.1
1
MARCKS SIK1
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CONCLUSION 
Our study aimed at identification of novel mRNA-miRNA target pairs that are hypothesized to 
play a role in breast cancer through an mRNA- miRNA interaction map analysis of microarray 
data and experimental validation of selected set of mRNAs. From mRNA microarray expression 
analysis, we found that the total number of differentially expressed genes in breast cancer is 225, 
out of which 73 are down regulated and 152 are up-regulated. Further, from miRNA expression 
analysis we found out that the total number of differentially expressed miRNAs in breast cancer 
is 94, out of which 82 are down-regulated and 12 are up-regulated. From the target interaction 
map analysis, we found that 7 miRNAs showed specific target binding for 25 genes, out of which 
these 3 pairs, hsa-miR-27a–MARCKS, hsa-miR-27a–SIK1 and hsa-miR-21–BTG2 are seen to be 
novel target pairs. MARCKS, SIK1 and BTG2 being tumor suppressor genes are seen to be 
significantly down regulated in breast cancer. hsa-miR-21 and hsa-miR-27a  being oncomiRs are 
seen to be highly up regulated in breast cancer because of their property to induce metastasis. 
The over expression of MARCKS and SIK1 can strongly repress the proliferation of cancer cells. 
The lower expression of hsa-miR-21 and hsa-miR-27a can even contribute in suppressing 
metastasis in breast cancer. Therefore, hsa-miR-27a–MARCKS, hsa-miR-27a–SIK1 and hsa-
miR-21–BTG2 have been hypothesized to be novel target pairs which can be further 
experimentally validated. Therefore, a better perceptive about the miRNA-gene networks and 
cellular pathways can be a promising concept in understanding and further elucidating the role of 
miRNAs involved in breast cancer pathogenesis and thereby may revolutionize the future of 
breast cancer therapeutics. 
 
 
 
 
 
 
 
  
 
FUTURE PROSPECTIVES 
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FUTURE PROSPECTIVES 
The effectiveness of miRNA-based breast cancer therapy can be a landmark in breast cancer 
studies. Identification of the genome-wide targets of miRNAs is a promising approach which can 
be experimentally validated to have a vital role in breast cancer. Henceforth, with a better 
perceptive about the gene networks and their cellular pathways regulated by miRNAs, the 
elucidation of breast cancer pathogenesis and therapeutics can be facilitated. Furthermore, 
experimental validation of hsa-miR-27a–MARCKS, hsa-miR-27a–SIK1 & hsa-miR-21–BTG2 
through Luciferase Reporter Assay or any other molecular techniques will strengthen the 
foundation of miRNA-mediated regulation in breast cancer. Subsequent analysis of these novel 
miRNA-target pairs will enhance our understanding to manipulate pathways/networks for 
treatment of breast cancer through miRNA therapeutics. 
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